Disease relevance of Trimebutine maleate

• Effects of trimebutine maleate on gastric motility in patients with gastric ulcer [1].
• The effect of trimebutine maleate on gastric emptying in patients with non-ulcer dyspepsia [2].
• Effects of trimebutine maleate (TM) on intestinal motility in short bowel syndrome (SBS) were studied in conscious canines in both acute and chronic phases following 80% massive distal small bowel resection (MSBR) [3].

High impact information on Trimebutine maleate

• Local actions of trimebutine maleate in canine small intestine [4].
• The effects of trimebutine maleate on cytosolic free Ca2+ and force transitions in the guinea-pig taenia cecum were studied by fura-2 fluorometry and tension recording [5].
• The effects of trimebutine maleate on [3H]nitrendipine binding to guinea-pig ileal smooth muscle membranes and Ca2(+)-induced contraction of the taenia cecum were studied [6].
• Effect of trimebutine maleate on sinus node pacemaker activity of the rabbit [7].
• Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC-MS/MS method [8].

Biological context of Trimebutine maleate

• The action of trimebutine maleate on gastrointestinal motility is mediated by opiate receptors in human subjects [9].
• The major effect of trimebutine maleate appears to be a shortening of the lag time at the start of gastric emptying probably via its anticholinergic activity [10].
• This method was applied to studying the pharmacokinetics and tissue distribution after a single dose of trimebutine maleate was administrated to the rats [11].
• When TM was given with meals, the postprandial period without duodenal migrating myoelectric (or motor) complexes (MMCs) was shorter than in those given meals only [3].
• In conclusion, oral TM administration can produce a more appropriate intestinal condition for the next food intake and make enteral nutrition possible even in the acute phase after MSBR [3].

Anatomical context of Trimebutine maleate

• Effect of trimebutine maleate on emptying of stomach and gallbladder and release of gut peptide following a solid meal in man [10].
• Effects of trimebutine maleate on delayed rectifier K+ currents in guinea-pig ventricular myocytes [12].
• BACKGROUND: Trimebutine maleate is a prokinetic agent that acts directly on the smooth muscle of the GI tract [8].
• The effects of trimebutine maleate on electrical activity in guinea-pig isolated papillary muscles and rabbit sino-atrial nodes have been studied by means of a standard microelectrode method [13].
• Effect of trimebutine maleate on the contractile response of the isolated ileum from diabetic rats [14].

Associations of Trimebutine maleate with other chemical compounds

• The influence of oral administration and intravenous infusion of trimebutine maleate (TMB) and N-desmethyl TMB (NDTMB), its main metabolite, was investigated in conscious dogs equipped with chronically implanted strain-gauges [15].
• Other agents with prokinetic effects on intestinal motility, i.e., cisapride, domperidone, metoclopramide, and trimebutine maleate did not have a favorable effect [16].
• The effects of trimebutine maleate (TM-906) on electrical and mechanical activities of smooth muscles of the guinea-pig stomach were investigated using a microelectrode and isometric tension recording methods [17].
• Prifinium bromide provided a marked antispasmodic effect on the ascending and sigmoid colons; the inhibitory effect of trimebutine maleate was limited to the ascending colon [18].
• Trimebutine tablets (dimethylamino-2-phenyl-2-n-butyl-3,4,5- trimethoxybenzoate maleate, CAS 34140-59-5, reference) and a new tablet formulation (Eurogalena, test) were administered in 24 healthy volunteers of both sexes according to a cross-over design, in a single dose of one 100 mg tablet of each formulation [19].

Gene context of Trimebutine maleate

• We investigated the effect of orally administered trimebutine maleate on gastric and gallbladder emptying and on the release of gut peptide, pancreatic polypeptide (PP), and gastrin in humans for 120 min after ingestion of a solid meal [10].
• The limit of quantitation was 1 ng/ml for trimebutine maleate, TM-MPB and APB, and 50 ng/ml for TMBA [20].
• A simple and sensitive HPLC method has been developed to measure trimebutine (CAS 39133-31-8, maleate: CAS 34140-59-5) and its main metabolite desmethyl-trimebutine in human plasma [21].
• Four antispasmodic preparations (prifinium bromide, propinox, trimebutine maleate and phloroglucinol + trimethylphloroglucinol) identical to those in Part I, study of the dog, were used [18].

Analytical, diagnostic and therapeutic context of Trimebutine maleate

• This method has been successfully applied to the pharmacokinetic study of trimebutine maleate in rabbit blood following oral administration of 200 mg/kg [22].
• Pharmacokinetic study of trimebutine maleate in rabbit blood using in vivo microdialysis coupled to capillary electrophoresis [22].
• In vivo microdialysis was used together with capillary electrophoresis (CE) to monitor the concentration of trimebutine maleate (TM) in rabbit blood [22].
• After treatment with trimebutine maleate, no significant difference has been observed in the mean symptom score of patients with prolonged gastric emptying [2].

References